Our client had a novel “one and done” gene therapy for an ultra-orphan disease. Despite previous payer research, the client lacked direction in which patient segments to target, what list to net pricing strategy to take, and what net price they could achieve. They needed an efficient and quantitative solution to inform their key development decisions.
Back to Case Studies
The “one and done” gene therapy made payers uncertain
Because of the one-time administration, payers were uncertain around the longevity of the benefit that would be provided outside of the payment year. Our client was eager to quantify how this uncertainty would affect their price potential – and knew they needed more than payer interviews to understand this.
Multiple patient segment and product profile scenarios required an efficient modeling approach
Our client had multiple product profiles and patient population scenarios to consider in their price strategy. To leave no stone unturned, they needed an approach that could efficiently quantify the therapy’s price potential in each scenario and deliverables which easily communicated scenario price differences…
…read how Behavior-Based Pricing™ did just that.